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The Authors Reply: We agree with Hirsch1 that an
appropriate terminology for the fall in drug-induced
estimated glomerular filtration rate (eGFR) that we observed2
may increase awareness for this phenomenon. We could
support the term ‘Pre-renal success’. However, before
adopting this term, a note of caution should be made. The
initial fall in GFR during renin–angiotensin–aldosterone
system inhibition is highly variable between individuals,
and discordant with the initial response in blood pressure or
albuminuria. Thus, a lack of initial GFR fall in the setting of a
reduction in albuminuria or blood pressure is no reason
to discontinue therapy. In addition, the beneficial initial fall
in GFR should be differentiated from the non-beneficial
fall (such as with a renal artery stenosis). Finally, the
phenomenon of ‘Pre-renal success’ is well described for
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers (ARBs). It is even described as an effect of
low-protein diet.3 Whether it applies to other interventions
needs to be investigated.
Ring4 questions whether the initial eGFR fall is also
associated with less end-stage renal disease (ESRD) incidence.
This is not so easy to test, since patients who have
a ‘steep slope’ of eGFR loss after start of ARB therapy are
also those patients who may likely end faster in ESRD.
Unfortunately, we have no eGFR slope of each patient
before starting ARB therapy (which would have allowed us
to see the true additional effect of ARB therapy on the
eGFR slope). Therefore, we used the placebo-treated
group for comparison. As shown in Table 3, the incidence
rates for doubling of serum creatinine level or ESRD were
markedly lower in losartan-treated subjects with an initial
fall in eGFR compared with placebo-treated patients with
a similar initial fall in eGFR. Similar results were seen for
ESRD alone.
We fully agree with Ring4 that serum creatinine levels
must be measured in nephrology trials several months after
stopping therapy to test whether GFR will return in the
direction of baseline.5,6 Unfortunately, the RENAAL trial did
not record eGFR values after cessation of therapy. Impor-
tantly, however, Apperloo et.al.7 tested this withdrawal effect
previously and showed that after discontinuation of anti-
hypertensive therapy the initial GFR fall is reversible, even
years after initiating treatment.
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Clinical pharmacists and patients
with chronic kidney disease
To the Editor: We read with interest the article by Matzke
et al.1 on ‘Drug dosing considerations in patients with acute
and chronic kidney disease’. We were surprised to read that
only the clinical practice recommendation for patients with
acute kidney injury advocated for ‘a patient-centered team
approach that includes an ICU pharmacist y to prevent
medication-related problems and enhance safe and effective
medication use.’ No mention was made of a team approach
including a renal pharmacist in the clinical practice
recommendations for patients with chronic kidney disease
(CKD), or those receiving peritoneal dialysis (PD) or
hemodialysis (HD).
A recent systematic review noted that studies of renal
clinical pharmacists have shown higher proportions of patients
achieving hemoglobin, glycemic and blood pressure control
targets, decreased microalbuminuria, increased patient medica-
tion knowledge, decreased hospitalization rates, and improved
quality of life.2 Studies examining an interprofessional model
of care, which included a pharmacist, vs. nephrologist care
alone in patients with CKD have demonstrated decreased
hospitalizations and mortality with a signiﬁcantly greater num-
ber of patients on angiotensin-converting enzyme inhibitors,
sodium bicarbonate, and iron supplements.3
Nephrology team models in which pharmacists are key
members in the care of patients with CKD and receiving
dialysis are commonly found in Canada and the United
Kingdom. Our Canadian provincial renal program currently
provides funding for pharmacists at a ratio of 1 pharmacist
for every 100 HD patients, 1 pharmacist for every 200 PD or
home HD patients, and 1 pharmacist for every 300 renal
clinic patients.4
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Regarding ‘Early postoperative
serum cystatin C predicts severe
acute kidney injury following
pediatric cardiac surgery’
To the Editor: We read with interest the recent article by
Zappitelli et al.1 We have three remarks to press on.
The classiﬁcation in mild and severe acute kidney injury
(AKI) as described on page 661 does not correspond to the
one by the Acute Kidney Injury Network. In fact, need for
dialysis should be classiﬁed as stage 3. Furthermore, both the
proposed stages include ‘need for dialysis’ as a condition,
which puzzled us a bit.
We are also confused by the use for different variables of
quintiles or tertiles: why not to use only quintiles?
However, the more important fact, it seems to us, is the
problem of whether all the cystatin C values contained
in the 5th or 3rd percentiles are a true expression of a
deranged renal function rather than that of analytical
imprecision. Using the available data on biological varia-
bility2,3 and an estimated laboratory analytical coefﬁcient
of variation of 4.5% (as the authors do not report their
own one), the calculated reference change value4 for
cystatin C is around 25%. This means that in a single indi-
vidual, only a cystatin change 425% between two measure-
ments can detect a signiﬁcant change in his/her renal
function. Hence, the questions are ‘How many patients in
the 5th and 3rd percentiles for predicting AKI fall below
the reference change value?’ and ‘With this limitation, is
early postoperative cystatin C still effective in predicting
severe AKI?’
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The Authors Reply: We thank Gambaro et al.1 for
their letter. Below are the clarifications for the three
questions raised. First, our outcomes were ‘mild’ or stage
1 acute kidney injury (AKI) or worse (including higher
AKI stages and dialysis) and ‘severe’ or stage 2 AKI
or worse (including stage 3 and dialysis). Dialysis
was correctly included in both the AKI definitions to
assure that patients receiving dialysis, but not fulfilling
serum creatinine (SCr) criteria, were categorized as having
AKI.2 Second, they queried our use of quintiles to
evaluate cystatin C (CysC) values (mg/dl) vs. tertiles to
evaluate % CysC change. We would have preferred
quintiles (more granularity) for all analyses but event rates
within quintile groups were very low for stage 2 AKI,
limiting us to analysis of tertiles. Finally, they note the
issue of CysC biological variability. Although contro-
versial,3 CysC may have higher intraindividual variation
than SCr.4 CysC measurement imprecision can contribute
to subject misclassification in given percentile groups;
we measured all samples in a single batch in a CLIA-
approved clinical laboratory, which would reduce mea-
surement variation. We reported our coefficient of
variation for CysC measurement as 1.1% (page 660).2
Importantly, such misclassification and increased vari-
ability would lead to decreased likelihood of finding
an association with the study outcome. In addition,
the third tertile of % CysC change was composed of
patients with 4 to 143% CysC change from baseline
(Table 3).2 The association with AKI should only get
stronger if we eliminated patients in the lower end (o25%
CysC change).
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